Skip to content

Improvement of joint pain and safety by ingestion of supplement containing glucosamine: a randomized, double blind, placebo-controlled study

Improvement of joint pain and safety by ingestion of supplement containing glucosamine: a randomized, double blind, placebo-controlled study - Improvement of joint pain and safety by ingestion of supplement containing glucosamine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020137
Enrollment
50
Registered
2015-12-09
Start date
2015-12-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Intake test sample for 16 weeks Intake placebo for 16 weeks

Sponsors

Japan clinical trial association
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and female between 30 and 69 years of age

Exclusion criteria

Exclusion criteria: 1. Subjects with joint pain caused by gout or rheumatism 2. Subjects with surgical experience for knee or elbow 3. Subjects with a history of fracture or sprain within the past 3 months 4. Subject with a past history of diseases in heart, kidney, liver, digestive organ, blood vessels or metabolism 5. Subjects who consume food or medicinal product containing glucosamine, chondroitin or hyaluronan 6. Subjects with food allergies 7. Subjects who are pregnant or lactating 8. Subjects who are judged as unsuitable for the study by the investigator for other reasons

Design outcomes

Primary

MeasureTime frame
2-step test (locomotion test), subjective evaluation (J-KOOS, JKOM, HAQ, ODI) <before and after ingestion of supplement for 16 weeks>

Secondary

MeasureTime frame
safety <before and after ingestion of supplement for 16 weeks>

Countries

Japan

Contacts

Public ContactHirohisa Kojima

Japan clinical trial association N.A.

info@yakujihou.org03-6457-4666

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026